Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Short-term treatment of hypertension when oral therapy is not feasible or desirable
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion of 5 mg/hour initially, titrated by 2.5 mg/hour every 15 minutes up to 15 mg/hour for acute hypertension. Typical infusion rate: 5-15 mg/hour.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life is approximately 2-4 hours in healthy adults; prolonged to about 7 hours in cirrhosis or hepatic impairment.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Hepatic via CYP3A4 and CYP2C8
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 35% of metabolites.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
>95% bound primarily to albumin.
Low protein binding; 0–11% bound, primarily to albumin.
0.6-1.5 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%; Oral: approximately 35% due to extensive first-pass metabolism.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No dosage adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific dose reduction recommended but monitor closely.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
In Child-Pugh Class A or B, reduce initial infusion rate to 2.5 mg/hour and titrate slowly. Avoid use in Child-Pugh Class C due to significant accumulation.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
For children ≥2 years: Initial intravenous infusion of 0.5-1 mcg/kg/minute, titrate by 0.5 mcg/kg/minute every 5-15 minutes to desired effect. Maximum: 5 mcg/kg/minute.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Initiate at lower end of dosing range (2.5-5 mg/hour intravenous infusion) and titrate slowly due to increased sensitivity and potential for hypotension.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
No FDA boxed warning.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Use caution in patients with heart failure, hepatic impairment, renal impairment, or acute cardiovascular disease. May cause hypotension, tachycardia, and peripheral edema. Monitor blood pressure and heart rate during infusion. Avoid abrupt discontinuation. Use with caution in patients with coronary artery disease due to possible reflex tachycardia.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to nicardipine or any component,Advanced aortic stenosis,Patients with known hypersensitivity to dihydropyridine calcium channel blockers
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Grapefruit products (fruit and juice) should be avoided as they inhibit CYP3A4 metabolism of nicardipine, increasing its serum concentration and risk of hypotension and other adverse effects. No other significant food interactions known.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
NICARDIPINE (CARDENE) - Teratogenic risk profile: First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: No increased risk of major malformations reported; potential for maternal hypotension and fetal hypoxia with high doses. Avoid use in pregnancy-induced hypertension unless benefit outweighs risk.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
NICARDIPINE (CARDENE) - Lactation summary: Excreted into breast milk in low concentrations (M/P ratio approximately 0.7); no adverse effects reported in infants. Use with caution, especially in preterm infants due to immature hepatic metabolism.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
NICARDIPINE (CARDENE) - Dosing adjustments in pregnancy: Pregnancy increases volume of distribution and clearance; dose requirements may be higher. Start at low end of dosing range and titrate to effect, monitoring for hypotension. Intravenous infusion: 5 mg/hour initially, increased by 2.5 mg/hour every 5-15 minutes to a maximum of 15 mg/hour.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Cardene (nicardipine) IV is a dihydropyridine calcium channel blocker used for short-term treatment of hypertension when oral therapy is not feasible. It has rapid onset and is titratable. Monitor for hypotension, reflex tachycardia, and peripheral edema. Use with caution in patients with aortic stenosis, coronary artery disease, or heart failure. It is compatible with 0.83% sodium chloride; avoid adding other drugs. Protect from light. Titrate based on blood pressure response. Hypotension may be profound in volume-depleted patients.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is given intravenously to lower your blood pressure. Report any dizziness, lightheadedness, or fainting immediately.,You may experience swelling in your legs or ankles. Notify your healthcare provider if this becomes bothersome.,Avoid sudden changes in position (e.g., standing up quickly) to prevent falls.,Do not consume grapefruit or grapefruit juice while on this medication, as it can increase the drug's effects and risk of side effects.,Inform your doctor if you have a history of liver or kidney disease, heart problems, or if you are pregnant or breastfeeding.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is a Electrolyte that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is: Intravenous infusion of 5 mg/hour initially, titrated by 2.5 mg/hour every 15 minutes up to 15 mg/hour for acute hypertension. Typical infusion rate: 5-15 mg/hour.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category A/B. NICARDIPINE (CARDENE) - Teratogenic risk profile: First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimeste. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.